Business Context and Reporting Period
This Form 6-K filing covers the month of December 2021 for BiondVax Pharmaceuticals Ltd. (note: the request metadata lists "Scinai Immunotherapeutics Ltd.", but the filing text identifies the registrant as BiondVax Pharmaceuticals Ltd.). The report discloses material corporate events occurring between December 27 and December 29, 2021.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial disclosure relates to a capital raise:
- Capital Raised: $9.8 million from a follow-on underwritten offering of American Depositary Shares (ADSs).
- Offering Details: The amount includes the full exercise of the underwriter's over-allotment option.
Material Changes
Two significant corporate actions were reported:
- Board Election: At the Annual General Meeting of Shareholders on December 27, 2021, shareholders approved all proposed resolutions, including the election of Mr. Jay Green (former CFO of GSK's Global Vaccines Business) to the Board of Directors.
- Capital Raise: On December 29, 2021, the Company successfully closed the aforementioned $9.8 million offering.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, operational outlook, specific risks, contingencies, or unusual items beyond the announcement of the completed offering and board election.
Investor Verification Checklist
- Verify the final share count and dilution impact resulting from the $9.8 million follow-on offering.
- Confirm the specific role and compensation structure of the newly elected board member, Mr. Jay Green.
- Review the use of proceeds from the capital raise as detailed in the accompanying press release (Exhibit 99.2).